Trikafta Overdose in an Adolescent Female with Cystic Fibrosis: A Case Report

Casey G. Contreary\textsuperscript{1} and Jessica E. Seay\textsuperscript{1}

\textsuperscript{1} Louisiana State University Health & Science Center School of Medicine

**Introduction:** Trikafta (Elexacaftor/Ivacaftor/Tezacaftor) is triple combination therapy approved for the treatment of cystic fibrosis. It was approved in the USA in October 2019, and there are no previous records of a Trikafta overdose in a CF patient or caregiver with access to this medication.

**Case Report:** A 15 yo female cystic fibrosis patient with a history of depression intentionally ingested 42 Trikafta (28 Elexacaftor 100mg/Tezacaftor 50mg/Ivacaftor 75mg and 14 Ivacaftor 150mg) in a suicide attempt. The patient regretted the ingestion and self-induced vomiting less than one hour later. She was stable at presentation and remained so throughout the duration of her hospitalization. She was treated supportively and managed with serial laboratory monitoring trending CMP and PT/INR BID. The primary laboratory finding was an elevation of aminotransferases that peaked at 140/148 on day 6 post ingestion, last recorded values were 58/44 42 days post ingestion. CK and APTT were within normal ranges at admission. Additionally, the patient did not experience hyperbilirubinemia.

**Discussion:** The objective of this clinical case report is to describe the presentation and management of a patient with excessive Trikafta ingestion. Due to the prevalence of anxiety and depression among cystic fibrosis patients and caregivers, there is concern for additional cases of Trikafta overdose as the use of this medication becomes more widespread.